$6.31
+0.38 (+6.50%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ACRS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
33 interventional · 28 with posted results
Held by 10 tracked-famous managers (Balyasny Asset Management L.P., CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., +5 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706Percent Change in Eczema Area and Severity Index (EASI)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: ATI-045, Placebo | Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema | 110 | Aug 2026 | ≤ 12 d | 2026-03-25 |
| Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisNCT06585202Incidence and severity of treatment emergent adverse events (TEAEs)Open-label · Treatment | Phase 2 | Completed | Drug: ATI-2138 | Atopic Dermatitis | 14 | 2025-03-13actual | — | 2026-03-12 |
| Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisNCT05511519Proportion of patients achieving ACR20 at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: ATI-450, Placebo Oral Tablet | Psoriatic Arthritis | 47 | 2023-12-06actual | — | 2024-11-27 |
| Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisNCT05432596Percentage change from baseline in Eczema Area and Severity Index Score (EASI) score at Week 4 (Day 28)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle | Atopic Dermatitis | 250 | 2023-10-26actual | — | 2024-10-26 |
| ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)NCT05279417Proportion of patients achieving ACR20 at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID | Rheumatoid Arthritis | 251 | 2023-09-05actual | — | 2024-09-05 |
| ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05216224results2026-01-07Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATI-450, Placebo oral tablet | Hidradenitis Suppurativa | 95 | 2022-12-23actual | — | 2026-01-07 |
| Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisNCT04598269results2023-09-28Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATI-1777, Vehicle | Atopic Dermatitis | 50 | 2021-04-08actual | — | 2023-09-28 |
| Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)NCT04524858results2023-09-21Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Due to patient enrollment challenges stemming from the COVID-19 pandemic, Aclaris has decided to focus its efforts and resources on other immuno-inflammatory diseases. | Drug: ATI-450 | Cryopyrin-Associated Periodic Syndrome | 1 | 2021-02-25actual | — | 2023-09-21 |
| Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RANCT04247815results2023-03-29The Primary Outcome Measure is the Determination of the Safety and Tolerability of ATI-450 Plus Methotrexate in Patients With Moderate to Severe Rheumatoid Arthritis: Adverse Events (AEs)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATI-450, Placebo oral tablet, Methotrexate | Rheumatoid Arthritis | 25 | 2021-02-04actual | — | 2023-03-29 |
| Safety Study of A-101 Topical Solution for the Treatment of Common WartsNCT03812510results2020-11-23Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common WartsOpen-label · TreatmentStudy Protocol ↗ · Informed Consent Form ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: A-101 | Common Wart | 426 | 2019-11-27actual | — | 2020-11-23 |
| A Study of ATI-50002 Topical Solution for the Treatment of VitiligoNCT03468855results2020-11-30Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline to Week 24Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: ATI-50002 topical solution | Vitiligo | 34 | 2019-10-16actual | — | 2020-11-30 |
| A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionNCT03495817results2020-12-09Mean Change From Baseline in Target Area Hair Count (TAHC)Open-label · TreatmentStudy Protocol ↗ · Informed Consent Form ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATI-50002 | Androgenetic Alopecia | 31 | 2019-10-15actual | — | 2020-12-09 |
| ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)NCT03759340results2020-09-17Change in the Severity of Alopecia Tool (SALT) ScoreOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: ATI 502 0.46% Topical Solution | Alopecia Areata, Alopecia Universalis, Alopecia Totalis | 56 | 2019-09-11actual | — | 2020-10-06 |
| Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)NCT03315689results2020-07-02Double Blind Period: ATI-50002 Levels in Scalp Biopsy (ng/g) - Pharmacodynamic (PD) Population at Day 2 and Day 29Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Vehicle, ATI-50002 | Alopecia Universalis (AU), Alopecia Totalis (AT) | 11 | 2019-06-20actual | — | 2020-07-02 |
| Study of A-101 Topical Solution for the Treatment of Common WartsNCT03687372results2020-10-05The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60)Randomized · Quadruple-masked · TreatmentStatistical Analysis Plan ↗ · Informed Consent Form: ICF (ages 12-17) ↗ · Study Protocol ↗ · Informed Consent Form: Main ICF ↗ · Informed Consent Form: ICF (ages 7-11) ↗ · Informed Consent Form: PCF Photography ↗ | Phase 3 | Completed | Drug: A-101 · Other: vehicle | Common Wart | 503 | 2019-06-20actual | — | 2020-10-05 |
| ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia TotalisNCT03594227results2020-09-16Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24Randomized · Triple-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose), Placebo | Alopecia | 87 | 2019-06-06actual | — | 2020-09-16 |
| A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisNCT03585296results2020-02-06Number of Subjects withTreatment-Emergent Adverse Events (Safety and Tolerability)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATI-502 | Atopic Dermatitis | 22 | 2019-04-25actual | — | 2020-02-17 |
| A Study of A-101 Topical Solution for the Treatment of Common WartsNCT03691831results2020-10-05The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Completed | Drug: Active · Other: Vehicle | Common Wart | 502 | 2019-04-21actual | — | 2020-10-27 |
| A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataNCT03354637results2020-06-05Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24Randomized · Double-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Terminatedsponsor's stated reason: The double-blind primary endpoint was not met. Open Label Extension period halted as a result. | Drug: ATI-50002 high dose, ATI-50002 low dose, Placebo | Alopecia Areata | 129 | 2019-04-18actual | — | 2020-06-05 |
| A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa NigraNCT03224598results2020-03-17Physician's DPN Lesions AssessmentRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: A-101 Topical Solution 40% | Dermatosis Papulosa Nigra | 39 | 2019-01-08actual | — | 2020-03-30 |
| An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic KeratosesNCT03487588results2019-10-02Subject SatisfactionOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: A-101 Topical Solution | Seborrheic Keratosis | 41 | 2018-11-14actual | — | 2019-10-02 |
| Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataNCT03551821results2019-12-11Clinician's Eyebrow AssessmentOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATI-50002 | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | 1 | 2018-11-06actual | — | 2019-12-11 |
| Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With RosaceaNCT03380390results2019-06-28Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 4 | Completed | Drug: Oxymetazoline HCL 1.0% Cream · Device: Energy-Based Therapy | Rosacea | 46 | 2018-06-15actual | — | 2019-09-04 |
| A Phase2 of A-101 Topical Solution in Subjects With Common WartsNCT03210337results2019-05-01Mean Change in Physician's Wart Assessment Score From Baseline to Day 57Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: A-101 Topical Solution, A-101 Vehicle Solution | Common Wart | 157 | 2018-03-16actual | — | 2019-05-01 |
| A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common WartsNCT03278028results2019-03-29Physician's Wart AssessmentRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: A-101 Topical Solution, A-101 Vehicle Solution | Common Wart | 159 | 2018-03-01actual | — | 2019-04-09 |
| A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic KeratosisNCT03148691results2019-05-06Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: A-101 | Seborrheic Keratosis | 253 | 2018-02-28actual | — | 2019-05-06 |
| A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.NCT02667236results2017-11-13Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion AssessmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: A-101 Solution · Other: Vehicle Solution | Seborrheic Keratosis | 450 | Oct 2016actual | — | 2018-02-06 |
| A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic KeratosisNCT02667275results2017-11-13Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment ScaleRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: A-101 Solution · Other: Vehicle Solution | Seborrheic Keratosis | 487 | Oct 2016actual | — | 2018-02-06 |
| An Open-Label Safety Study of A-101 SolutionNCT02667288results2017-11-17Proportion of Subjects With Lesion ClearanceOpen-label · Treatment | Phase 3 | Completed | Drug: A-101 Solution | Seborrheic Keratosis | 147 | Oct 2016actual | — | 2018-02-07 |
| A Study of A-101 Solution in Subjects With Common Warts.NCT02669862results2018-12-07Efficacy Based on Mean Change in Physician Wart Assessment Over TimeRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: A-101 Solution 40, A-101 Solution 45, Vehicle Solution | Common Warts | 98 | 2016-09-16actual | — | 2018-12-07 |
| Study of A-101 for the Treatment of Seborrheic KeratosisNCT02260180results2018-12-06Percentage of PLA Responders With Target Lesion Clear (PLA = 0) in Each Arm at Visit 8.Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: A-101 | Seborrheic Keratosis | 119 | Mar 2015actual | — | 2020-12-02 |
| Dose-Response Profile of A-101 in Subjects With Seborrheic KeratosisNCT02160626results2018-12-07Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution | Seborrheic Keratosis | 172 | Dec 2014actual | — | 2019-01-03 |
| Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic KeratosisNCT01986920results2018-12-11Mean Change in Physician Lesion Assessment ScaleRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle | Seborrheic Keratosis (SK) | 35 | 2014-02-25actual | — | 2018-12-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19